ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 399

Musculoskeletal Comorbidities after Total Knee Replacement for Osteoarthritis

MaryAnn Zhang1, Faith Selzer2, Elena Losina1, Jamie E. Collins3 and Jeffrey N. Katz1, 1Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, 2Orthopedic Surgery, Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 3Department of Orthopedic Surgery, Orthopedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: comorbidity and osteoarthritis, Musculoskeletal, Total Knee Arthroplasty (TKA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, October 21, 2018

Title: Orthopedics, Low Back Pain and Rehabilitation Poster – ACR/ARHP

Session Type: ACR/ARHP Combined Abstract Session

Session Time: 9:00AM-11:00AM

Background/Purpose: For patients undergoing total knee replacement (TKR) for osteoarthritis (OA), preoperative musculoskeletal (MSK) complaints in areas beyond the index knee are common; however, the risk for new MSK comorbidities after TKR is not well studied.

Methods: We used data from the Adding Value in Knee Arthroplasty (AViKA) prospective cohort study on patients undergoing elective TKR for OA at a tertiary academic center. Preoperative questionnaires included demographics, data for Charlson Comorbidity Index, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and Function Scales, Mental Health Inventory-5 (MHI-5), Pain Catastrophizing Scale (PCS), and presence of MSK symptomatic areas by region (neck, hands/wrists/arms/shoulders, back, hips, non-index knee, and ankles/feet). Follow-up questionnaires including data on incident symptomatic areas were distributed at 3, 6, 12, 24, 36, and 48 months post-TKR. Cumulative incidence (number of new cases per number of subjects at risk) and incidence rates (number of new cases per person time) were calculated for each symptomatic area.  We used Poisson regression models to identify factors associated with incident MSK symptomatic areas.  Covariates with two-sided p-values < 0.05, or incidence rate ratio (RR) < 0.8, or RR >1.25 in univariate analyses were incorporated in the final parsimonious models.

Results: Among 308 patients undergoing elective TKR for OA, 87% were younger than 75 years and 60% were female.  One-quarter of subjects had at least one symptomatic area at baseline, and of those, non-index knee was the most common presurgical symptomatic area (10%). The cumulative incidence of any new MSK symptomatic area over 4 years was 45%, while the incidence rate was 192 per 1000 person-years (95% CI 153-242 per 1000 person-years). Cumulative incidence was highest for non-index knee (23%) and back (15%); incidence rates for non-index knee and back were 69 per 1000 person-years (95% CI 52-92 per 1000 person-years) and 53 per 1000 person-years (95% CI 38-74 per 1000 person-years) respectively. Based on the final Poisson model (Table), variables associated with developing an incident MSK symptomatic area after TKR included female sex (RR 1.51, 95% CI 1.13-2.04), body mass index ≥35 (RR 1.34, 95% CI 1.03-1.74), baseline index knee WOMAC function score ≥41 (RR 1.49, 95% CI 1.12-1.97), and symptoms consistent with anxiety/depression (MHI-5 <68) (RR 1.41, 95% CI 1.10-1.82). 

Conclusion: Incident MSK comorbidities, particularly in the non-index knee and back, will occur in roughly half of elective TKR recipients in the four years following TKR.  Factors associated with incident MSK comorbidities include female sex, obesity, worse baseline index knee function scores, and anxiety/depression.  Further study is needed to examine the long-term impact of these incident comorbidities on postoperative rehabilitation and quality of life.

Predictors of Incident MSK Comorbidity by Univariate and Multivariate Poisson Regression

Demographics

No Incident MSK Comorbidity

N (%)

Any Incident MSK Comorbidity

N (%)

Univariate

Multivariate

RR (95% CI)

RR (95% CI)

P-value

Age

—

    < 65 years

71 (44)

52 (40)

1.0 (ref)

—

    65-75 years

69 (43)

61 (47)

1.11 (0.84-1.46)

—

    > 75 years

22 (14)

18 (14)

1.06 (0.71-1.59)

—

Sex

0.006

    Male

77 (48)

38 (29)

1.0 (ref)

1.0 (ref)

    Female

85 (53)

93 (71)

1.58 (1.18-2.13)

1.51 (1.13-2.04)

BMI (kg/m2)

0.03

    <35

135 (85)

89 (70)

1.0 (ref)

1.0 (ref)

    ≥35

24 (15)

39 (30)

1.56 (1.21-2.00)

1.34 (1.03-1.74)

Medical comorbidities

Charlson comorbidity index

—

    0-1

100 (67)

73 (59)

1.0 (ref)

—

    ≥2

49 (33)

51 (41)

1.21 (0.93-1.57)

—

Orthopedic comorbidities

# of problematic areas at baseline

—

    0-1

151 (93)

116 (89)

1.0 (ref)

—

    ≥2

11 (7)

15 (11)

1.33 (0.93-1.90)

—

Baseline WOMAC paina

—

   0-40

102 (64)

59 (46)

1.0 (ref)

—

   ≥41

57 (36)

70 (54)

1.50 (1.16-1.94)

—

Baseline WOMAC functiona

0.006

   0-40

97 (60)

48 (37)

1.0 (ref)

1.0 (ref)

   ≥41

65 (40)

82 (63)

1.69 (1.28-2.21)

1.49 (1.12-1.97)

Mental health comorbidities

MHI-5 scoreb

0.008

   0-67

22 (14)

36 (27)

1.54 (1.19-1.98)

1.41 (1.10-1.82)

   68-100

140 (86)

95 (73)

1.0 (ref)

1.0 (ref)

PCS scorec

—

   <16

129 (80)

90 (70)

1.0 (ref)

—

   ≥16

32 (20)

38 (30)

1.32 (1.01-1.73)

—

*Subjects with 0 follow-up questionnaires were excluded from the analysis. 

a- WOMAC scores were transformed to a 0 to 100-point scale (100 worst).

b- MHI-5 = Mental Health Inventories 5 score.  Scores transformed to 0 to 100-point scale (0 worst).

c- PCS score = Pain catastrophizing scale score.  Score ≥ 16 was considered high pain catastrophizing.


Disclosure: M. Zhang, None; F. Selzer, None; E. Losina, Samumed, 5,JBJS, 5; J. E. Collins, None; J. N. Katz, None.

To cite this abstract in AMA style:

Zhang M, Selzer F, Losina E, Collins JE, Katz JN. Musculoskeletal Comorbidities after Total Knee Replacement for Osteoarthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/musculoskeletal-comorbidities-after-total-knee-replacement-for-osteoarthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/musculoskeletal-comorbidities-after-total-knee-replacement-for-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology